MedKoo Cat#: 462485 | Name: STAT3-IN-3
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3).

Chemical Structure

STAT3-IN-3
STAT3-IN-3
CAS#2361304-26-7

Theoretical Analysis

MedKoo Cat#: 462485

Name: STAT3-IN-3

CAS#: 2361304-26-7

Chemical Formula: C27H26BrN3O6S

Exact Mass: 599.0726

Molecular Weight: 600.48

Elemental Analysis: C, 54.01; H, 4.36; Br, 13.31; N, 7.00; O, 15.99; S, 5.34

Price and Availability

Size Price Availability Quantity
5mg USD 550.00 2 Weeks
10mg USD 900.00 2 Weeks
25mg USD 1,550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
STAT3-IN-3; STAT3 IN 3; STAT3 IN-3; STAT3-IN 3
IUPAC/Chemical Name
3-(4-(4-bromo-1,1-dioxidocinnamoyl)piperazine-1-carbonyl)-7-(diethylamino)-2H-chromen-2-one
InChi Key
LEVMMUZFAXTJOJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H26BrN3O6S/c1-3-29(4-2)18-9-8-17-14-20(27(34)37-22(17)15-18)25(32)30-10-12-31(13-11-30)26(33)24-16-19-21(28)6-5-7-23(19)38(24,35)36/h5-9,14-16H,3-4,10-13H2,1-2H3
SMILES Code
BrC1=C2C(S(C(C(N3CCN(C(C4=CC5=CC=C(N(CC)CC)C=C5OC4=O)=O)CC3)=O)=C2)(=O)=O)=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
STAT3-IN-3 induces apoptosis in breast cancer cells.
In vitro activity:
Pretreatment with STAT3-IN-3 significantly inhibited the upregulation of P-gp and Bcl-2 protein expression induced by the miRNA-221 mimic in Saos-2 cells; it also caused the Saos-2 cells to overcome DOX resistance induced by the miRNA-221 mimic. Reference: Biol Pharm Bull. 2021 Jun 1;44(6):861-868. https://pubmed.ncbi.nlm.nih.gov/33828027/
In vivo activity:
To be determined
Solvent mg/mL mM
Solubility
DMSO 5.0 8.33
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 600.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Liu Y, Liu X, Yang S. MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells. Biol Pharm Bull. 2021 Jun 1;44(6):861-868. doi: 10.1248/bpb.b21-00163. Epub 2021 Apr 8. PMID: 33828027.
In vitro protocol:
1. Liu Y, Liu X, Yang S. MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells. Biol Pharm Bull. 2021 Jun 1;44(6):861-868. doi: 10.1248/bpb.b21-00163. Epub 2021 Apr 8. PMID: 33828027.
In vivo protocol:
To be determined
1: Cai G, Yu W, Song D, et al. Discovery of fluorescent coumarin-benzo[b]thiophene 1, 1-dioxide conjugates as mitochondria-targeting antitumor STAT3 inhibitors. Eur J Med Chem. 2019;174:236-251. doi:10.1016/j.ejmech.2019.04.024